Toxoplasmosis, CerebralNCT07044037
Analysis of Cerebrospinal Fluid in Patients With Cerebral Toxoplasmosis at CHSD (2004-2024)
An observational study of Toxoplasmosis, Cerebral and Toxoplasmosis, run by Centre Hospitalier de Saint-Denis at 1 site in France.
Trial summary
This study looks at patients who were treated for cerebral toxoplasmosis at CHSD between 2004 and 2024. It focuses on analyzing their cerebrospinal fluid (CSF) to better understand the biological signs of the disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Toxoplasmosis, Cerebral, Toxoplasmosis, Meningitis
- How many people
- 53 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jul 2024to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: The study population includes adult patients (aged 18 years and older) who were hospitalized at the Centre Hospitalier de Saint-Denis (CHSD) between January 1, 2004, and March 31, 2024, with a principal or significant associated diagnosis of cerebral toxoplasmosis.
Who may be able to join
- Adult patients (age 18 years) hospitalized at CHSD between January 1, 2004 and March 31, 2024 for cerebral toxoplasmosis
Who cannot join
- Under 18 years ols
Trial locations and contacts
1 site in 1 country.
About this study
This study looks at patients who were treated for cerebral toxoplasmosis at CHSD between 2004 and 2024. It focuses on analyzing their cerebrospinal fluid (CSF) to better understand the biological signs of the disease. The goal is to see if CSF results can show signs of meningitis, even though it's not commonly reported, and to describe any co-infections, symptoms, brain imaging findings, and patient outcomes.
- Conditions
- Toxoplasmosis, Cerebral, Toxoplasmosis, Meningitis, HIV Infections, Cerebrospinal Fluid, Central Nervous System Infections
- Medical subject headings
- Toxoplasmosis, Cerebral, Toxoplasmosis, Meningitis, HIV Infections, Central Nervous System Infections
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measured: From hospital admission to completion of diagnostic lumbar puncture and initial treatment (typically within the first 7 days of hospitalization).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2025
- Study start1 Jul 2024
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Toxoplasmosis, CerebralStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 53 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier de Saint-Denis
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07044037
- Sponsor's protocol ID
- 0076_NEUROLOGIE
- Status last verified
- Jun 2025
- First submitted
- 12 Jun 2025
- Last updated
- 29 Jun 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Cerebrospinal Fluid in Patients With Cerebral Toxoplasmosis at CHSD (2004-2024)
- ClinicalTrials.gov ID
- NCT07044037
- Acronym / sponsor ID
- 0076_NEUROLOGIE
- Conditions
- Toxoplasmosis, Cerebral, Toxoplasmosis, Meningitis, HIV Infections, Cerebrospinal Fluid, Central Nervous System Infections
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 53 participants (actual)
- Lead sponsor
- Centre Hospitalier de Saint-DenisUniversity, hospital or other
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 29 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study looks at patients who were treated for cerebral toxoplasmosis at CHSD between 2004 and 2024. It focuses on analyzing their cerebrospinal fluid (CSF) to better understand the biological signs of the disease. The goal is to see if CSF results can show signs of meningitis, even though it's not commonly reported, and to describe any co-infections, symptoms, brain imaging findings, and patient outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The study population includes adult patients (aged 18 years and older) who were hospitalized at the Centre Hospitalier de Saint-Denis (CHSD) between January 1, 2004, and March 31, 2024, with a principal or significant associated diagnosis of cerebral toxoplasmosis.
Key inclusion criteria (1 listed)
- Adult patients (age 18 years) hospitalized at CHSD between January 1, 2004 and March 31, 2024 for cerebral toxoplasmosis
Key exclusion criteria (1 listed)
- Under 18 years ols
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: From hospital admission to completion of diagnostic lumbar puncture and initial treatment (typically within the first 7 days of hospitalization).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2025.
Related trials for Toxoplasmosis, Cerebral
RecruitingObservational study
Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital
Cerebral Toxoplasmosis
RecruitingObservational study
Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis
Toxoplasmosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Toxoplasmosis, Cerebral and Toxoplasmosis, run by Centre Hospitalier de Saint-Denis at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 (time frame: From hospital admission to completion of diagnostic lumbar puncture and initial treatment (typically within the first 7 days of hospitalization).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2025.